Received: 17 April 2021 | Revised: 12 November 2021 | Accepted: 15 December 2021DOI: 10.1002/npr2.12228CASE REPORTThe effectiveness of lamotrigine for persistent depressivedisorder: A case reportYusuke Matsuzaka1,2 | Kayoko Urashima1,2 | Shintaro Sakai1 | Yoshiro Morimoto1,2 |Shinji Kanegae1 | Hirohisa Kinoshita1,3 | Akira Imamura1,4 | Hiroki Ozawa1,21Department of Neuropsychiatry,Nagasaki University Hospital, Nagasaki, AbstractJapan Aim: Persistent depressive disorder (PDD) was first introduced in the Diagnostic and2Department of Neuropsychiatry, Statistical Manual of Mental Disorders 5th edition (DSM-5), which encompasses nu-Nagasaki University Graduate School ofBiomedical Sciences, Nagasaki, Japan merous different conditions, including dysthymia, recurrent major depressive disor-3Health Center, Nagasaki University, der, double depression, and chronic major depression. SSRIs are the first-line drugs forNagasaki, Japantreatment of PDD; however, not all patients respond to SSRI treatment.4Child and Adolescent PsychiatryCommunity Partnership Unit, Nagasaki Case presentation: We describe a woman who was diagnosed with PDD. At the ageUniversity Hospital, Nagasaki, Japan of 38, the patient presented with anxiety, reduced energy, marked tiredness, andCorrespondence sleep disturbances. She was prescribed with three antidepressants (paroxetine, du-Yusuke Matsuzaka, Department of loxetine, and mirtazapine), which were not effective in relieving her symptoms. SheNeuropsychiatry, Nagasaki UniversityGraduate School of Biomedical Sciences, was also prescribed bromazepam, which was also not effective. Subsequently, she852-8501, 1-7-1 Sakamoto, Nagasaki, was switched to lamotrigine, which resulted in a marked improvement in symptoms.Japan.Email: ysk.mtzk.1980@gmail.com The antidepressants and bromazepam were gradually tapered and discontinued.Conclusion: This case demonstrates that lamotrigine may be effective for treatingFunding informationThis work was supported by the Japan patients with antidepressant resistant PDD and suggests that it may be a promis-Society for the Promotion of Science ing alternative to combination therapy of antidepressants and benzodiazepines in the(JSPS) KAKENHI (grant number20K16629) (to Yu. M). treatment of PDD.KEYWORDSbipolar and related disorders, lamotrigine, persistent depressive disorder (PDD)1 | INTRODUCTION heterogeneity of the diagnosis, and these criticisms have continuedwith PDD, its latest classification. Several reports have examined thePersistent depressive disorder (PDD) was first introduced in the efficacy and acceptability of selective serotonin reuptake inhibitorsDiagnostic and Statistical Manual of Mental Disorders 5th edition (SSRIs) and tricyclic antidepressants in the treatment of PDD1 and(DSM-5), which encompasses numerous different conditions, in- have provided evidence for the efficacy of antidepressants in thecluding dysthymia (DST), recurrent major depressive disorder, dou- treatment of chronic depression. However, reports have shown thatble depression, and chronic major depression. Since its inception up to two-thirds of adult patients do not achieve remission with SSRIin the DSM-III, DST has been widely criticized for its significant treatment. Moreover, there is limited evidence identifying reliableThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,provided the original work is properly cited.© 2022 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society ofNeuropsychopharmacology|120 wileyonlinelibrary.com/journal/nppr Neuropsychopharmacology Reports. 2022;42:120–123.